CalciMedica positive data in Phase 2b Trial of Auxora™ in Acute Pancreatitis

 Statistically significant 100% reduction (p = 0.0027) in new-onset severe respiratory failure and 64.2% reduction (p = 0.0476) in new-onset persistent respiratory failure in combined high and medium dose Auxora patients versus combined low dose Auxora and placebo patients

Statistically significant stratified win ratio of 1.640 (p = 0.0372) for high dose Auxora compared to placebo

Clinically meaningful reduction observed for high dose Auxora patients compared to placebo in additional key endpoints: new-onset necrotizing pancreatitis and time to medically indicated discharge

Conference call and webcast to review full data set from the Ph2b CARPO trial to be held at 12 p.m. ET/ 9 a.m. PT

Participant Webcast Link: https://app.webinar.net/4EanW4A2PXk

Click on the webcast link and complete the online registration form.

Upon registering, you will be connected to the online webcast.

Participant Dial-in Numbers: 1-646-357-8785 (US) and 1-800-836-8184 (international)

If prompted by the operator, ask to join the CalciMedica Phase 2b CARPO Full Data Set & Win Ratio call.

https://www.prnewswire.com/news-releases/calcimedica-to-present-late-breaking-positive-data-including-a-win-ratio-analysis-from-phase-2b-carpo-trial-of-auxora-in-acute-pancreatitis-ap-at-the-american-college-of-gastroenterology-acg-2024-annual-scientific-meeting-302290862.html